Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 64 for your search:
Drug:
aldesleukin
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment
Phase:
Phase IV
Type:
Supportive care, Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NIMH
Protocol IDs:
R01 MH071580
, DATR A3-NSS, NCT00352885
2.
Phase III Randomized Study of Resection With or Without Neoadjuvant and Adjuvant Perilymphatic Interleukin-2 and Adjuvant Radiotherapy in Patients With Previously Untreated Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
75 and under
Sponsor:
Other
Protocol IDs:
CNR-9506
, EU-95024, NCT00002702
3.
Phase III Randomized Study of High-Dose Aldesleukin With or Without gp100 Antigen in Patients With Locally Advanced or Metastatic Cutaneous Melanoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CCCGHS-NCI-T98-0085
, NCI-T98-0085, NCI-99-C-0051B, T98-0085, NCT00019682
4.
Phase III Randomized Study of High-Dose Versus Standard-Dose Cytarabine During Induction and Interleukin-2 Following Intensive Consolidation and Autologous Peripheral Blood Stem Cell Transplantation in Patients With Acute Myeloid Leukemia
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
15 to 60
Sponsor:
Other
Protocol IDs:
EORTC-06991
, NCT00004128, GIMEMA-EORTC-06991
5.
Phase III Randomized Study of Adjuvant Isotretinoin With or Without Monoclonal Antibody Ch14.18, Interleukin-2, and Sargramostim (GM-CSF) in Patients With Neuroblastoma Who Have Completed Myeloablative Therapy and Autologous Stem Cell Transplantation
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
30 and under at diagnosis
Sponsor:
NCI
Protocol IDs:
COG-ANBL0032
, ANBL0032, COG-P9842, NCT00026312
6.
Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 75
Sponsor:
Other
Protocol IDs:
BRD/04/1-D
, NCT00200577
7.
M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
A/100/0402
, NCT00477906
8.
Phase I/II Study of Immunotherapy With Armed Activated T Cells, Interleukin-2, and Sargramostim (GM-CSF) in Women With Stage IV Breast Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Other
Protocol IDs:
WSU-2006-130
, NCT00027807, RWMC-0635146, WSU-010307M1F, WSU-0312004412
9.
Phase I/II Pilot Study of Adoptive Immunotherapy With CD8+ WT1-Specific CTL Clones for Patients With Advanced Myelodysplastic Syndromes (MDS), Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), or Acute Lymphoblastic Leukemia (ALL) After Allogeneic Hematopoietic Stem Cell Transplant
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
75 and under
Sponsor:
NCI
Protocol IDs:
FHCRC-1655.00
, 5430, NCT00052520
10.
Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
20 to 75
Sponsor:
Other
Protocol IDs:
27MD02
, NCT00154713
11.
The Role of Peptide-Loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
pepDCIL2- HMO-CTIL
, NCT00279058
12.
Dendritic Cell Based Therapy of Renal Cell Carcinoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
UR0414
, NCT00197860
13.
Dendritic Cell Based Therapy of Malignant Melanoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
MM0413
, NCT00197912
14.
Aldesleukin in Patients With Metastatic Renal Cell Carcinoma and Metastatic Melanoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CPRL002A2201
, NCT00414765
15.
Phase I/II Study of Nonmyeloablative Lymphocyte-Depleting Preparative Chemotherapy Comprising Cyclophosphamide and Fludarabine Followed by Allogeneic Tumor-Reactive Lymphocyte Cell Line DMF5 and High-Dose Aldesleukin in Patients With Refractory Metastatic Melanoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0210
, 07-C-0210, NCT00537069
16.
Phase I/II Study of Adoptive Immunotherapy Comprising 2-Methyl-3-Butenyl-1-Pyrophosphate-Stimulated Gamma Delta T Cells, Aldesleukin, and Zoledronate in Patients With Stage IV Renal Cell Carcinoma and Lung Metastases
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
20 to 80
Sponsor:
Other
Protocol IDs:
TRIC-CTR-GU-05-01
, CTR GU 05-01, NCT00588913
17.
Phase I/II Study of Haploidentical Allogeneic Aldesleukin-Activated Natural Killer Cells and Aldesleukin Following Chemoimmunotherapy Comprising Rituximab, Fludarabine, and Cyclophosphamide in Patients With CD20-Positive Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UMN-2007LS064
, UMN-2007LS064, MT2007-12, UMN-0707M13561, NCT00625729
18.
Phase I/II Study of Nonmyeloablative Lymphodepleting Conditioning Comprising Cyclophosphamide and Fludarabine Phosphate Followed by Anti-HER-2 Gene-Engineered Autologous Peripheral Blood Lymphocytes and High-Dose Aldesleukin in Patients With Metastatic Cancer That Expresses HER-2
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-09-C-0041
, 09-C-0041, NCI-P07334, NCT00805987
19.
Phase I/II Study of Nonmyeloablative Lymphodepleting Conditioning Comprising Cyclophosphamide and Fludarabine Phosphate Followed by Anti-CEA TCR-Gene Engineered Autologous Lymphocytes and High-Dose Aldesleukin in Patients With Metastatic Cancer That Expresses CEA
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-09-C-0047
, 09-C-0047, NCI-P08404, NCT00809978
20.
Phase I/II Randomized Study of PG13-CD19-H3 (anti-CD19 CAR) Retroviral Vector-Transduced Peripheral Blood Lymphocytes With Versus Without A Nonmyeloablative Conditioning Regimen in Patients With Progressive B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-09-C-0082
, 09-C-0082, NCI-P08403, NCT00862069
21.
Phase I/II Study of 2G-1 T-Cell Receptor-Transduced Peripheral Blood Lymphocytes or Tumor Infiltrating Lymphocytes and Aldesleukin After a Nonmyeloablative Preparative Chemotherapy Regimen in Patients With Metastatic Renal Cell Carcinoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-09-C-0092
, 09-C-0092, NCI-P08417, NCT00870389
22.
Phase I/II Study of Cellular Adoptive Immunotherapy Comprising Autologous NY-ESO-1-Melanoma-Specific CD8+ T Cells With or Without Ipilimumab in Patients With Metastatic Melanoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
FHCRC-2225.00
, FHCRC-2225.00, IR-6881, BMS-CA184-062, NCT00871481
23.
Phase II Study of Adoptive Transfer of Cloned Lymphocytes With Interleukin-2 After Cyclophosphamide and Fludarabine in Patients With Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-99-C-0158
, NCI-T99-0078, T99-0078, NCT00019942
24.
Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Under 70
Sponsor:
Other
Protocol IDs:
271296-HMO-CTIL
, NCT00149006
25.
Immunochemotherapy for Metastatic Renal Cell Carcinoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 80
Sponsor:
Other
Protocol IDs:
1747CTIL
, Raphael Rubinov, NCT00226798
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
